Log in
Enquire now

Clinical Studies Sponsored by Karuna Therapeutics

Clinical Studies Sponsored by Karuna Therapeutics
Clinical Studies Sponsored by Regeneron Pharmaceuticals
Clinical Studies Sponsored by Fate Therapeutics
Clinical Studies Sponsored by Viome
List of patents in the Energy industry industry
List of funding rounds for Clustrix
Clinical Studies where
Trial Sponsor
is
Name
Description
NCT Number
Health Conditions in Trial
Clinical Trial Start Date
Study Completion Date
Clinical Trial Study Type
‌
A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of Xanomeline With Trospium Chloride Versus KarXT in Healthy Adult and Elderly Participants of Japanese Ethnicity and to Assess the Effect of Omeprazole on the PK of Xanomeline With Trospium Chloride in Healthy Adult Participants

NCT06605950
October 1, 2024
April 21, 2025
Interventional
‌
Study to Assess Safety and Effectiveness of Slowly Increasing Dose and Food Effect of KarXT in Participants With Schizophrenia

NCT06572449
‌
Schizophrenia
December 31, 2024
August 8, 2025
Interventional
‌
An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)

NCT04820309
‌
Schizophrenia
June 2, 2021
2024
Interventional
‌
A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-2)

NCT04659161
‌
Schizophrenia
December 16, 2020
May 24, 2022
Interventional
‌
A Study to Assess Safety and Efficacy of KarXT in Adult Patients With Schizophrenia

NCT03697252
‌
Schizophrenia
September 18, 2018
September 4, 2019
Interventional
‌
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)

NCT05511363
August 23, 2022
2025
Interventional
‌
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium

NCT02831231
‌
Schizophrenia
September 7, 2016
October 28, 2016
Interventional
‌
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease

NCT05980949
July 11, 2023
2026
Interventional
8 results
0 selected
8 results
0 selected
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us